{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:08Z","timestamp":1787028728334,"version":"build-2736575974"},"reference-count":65,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases","award":["R33AI140823"],"award-info":[{"award-number":["R33AI140823"]}]},{"name":"National Institute of Allergy and Infectious Diseases","award":["R21AI156100"],"award-info":[{"award-number":["R21AI156100"]}]},{"name":"Margaret Batts Tobin Foundation","award":["R33AI140823"],"award-info":[{"award-number":["R33AI140823"]}]},{"name":"Margaret Batts Tobin Foundation","award":["R21AI156100"],"award-info":[{"award-number":["R21AI156100"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Candidiasis is one of the most frequent nosocomial infections affecting an increasing number of at-risk patients. Candida albicans remains the most frequent causative agent of candidiasis, but, in the last decade, C. auris has emerged as a formidable multi-drug-resistant pathogen. Both species are fully capable of forming biofilms, which contribute to resistance, increasing the urgency for new effective antifungal therapies. Repurposing existing drugs could significantly accelerate the development of novel therapies against candidiasis. Here, we have screened the Repurposing Hub library from the Broad Institute, containing over 6000 compounds, in search for inhibitors of C. albicans and C. auris biofilm formation. The primary screen identified 57 initial hits against C. albicans and 33 against C. auris. Confirmatory concentration-dependent assays were used to validate the activity of the initial hits and, at the same time, establish their anti-biofilm potency. Based on these results, ebselen, temsirolimus, and compound BAY 11-7082 emerged as the leading repositionable compounds. Subsequent experiments established their spectrum of antifungal activity against yeasts and filamentous fungi. In addition, their in vivo activity was examined in the murine models of hematogenously disseminated C. albicans and C. auris infections. Although promising, further in vitro and in vivo studies are needed to confirm their potential use for the therapy of candidiasis and possibly other fungal infections.<\/jats:p>","DOI":"10.3390\/jof9090879","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:57:35Z","timestamp":1693205855000},"page":"879","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against Candida albicans and Candida auris Biofilms"],"prefix":"10.3390","volume":"9","author":[{"given":"Olabayo H.","family":"Ajetunmobi","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Wall","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Vidal Bonifacio","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucero A.","family":"Martinez Delgado","sequence":"additional","affiliation":[{"name":"Department of Healthcare Sciences, University of The Incarnate Word, San Antonio, TX 78209, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok K.","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Najvar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Floyd L.","family":"Wormley","sequence":"additional","affiliation":[{"name":"Department of Biology, Texas Christian University, Fort Worth, TX 76129, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoja P.","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-5122","authenticated-orcid":false,"given":"Nathan P.","family":"Wiederhold","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9513-7127","authenticated-orcid":false,"given":"Thomas F.","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-3270","authenticated-orcid":false,"given":"Jose L.","family":"Lopez-Ribot","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.chest.2021.08.081","article-title":"Risk factors for invasive Candida infection in critically ill patients: A systematic review and meta-analysis","volume":"161","author":"Schlattmann","year":"2022","journal-title":"Chest"},{"key":"ref_2","first-page":"e449","article-title":"Burden of candidemia in the United States, 2017","volume":"71","author":"Tsay","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wall, G., and Lopez-Ribot, J.L. (2020). Current antimycotics, new prospects, and future approaches to antifungal therapy. Antibiotics, 9.","DOI":"10.3390\/antibiotics9080445"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10123-018-0014-1","article-title":"The continuous changes in the aetiology and epidemiology of invasive candidiasis: From familiar Candida albicans to multiresistant Candida auris","volume":"21","author":"Quindos","year":"2018","journal-title":"Int. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1348-0421.2008.00083.x","article-title":"Candida auris sp. Nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a japanese hospital","volume":"53","author":"Satoh","year":"2009","journal-title":"Microbiol. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/14787210.2020.1750368","article-title":"Multidrug-resistant Candida auris: An epidemiological review","volume":"18","author":"Chakrabarti","year":"2020","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kean, R., Brown, J., Gulmez, D., Ware, A., and Ramage, G. (2020). Candida auris: A decade of understanding of an enigmatic pathogenic yeast. J. Fungi, 6.","DOI":"10.3390\/jof6010030"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41579-023-00861-x","article-title":"The WHO fungal priority pathogens list as a game-changer","volume":"21","author":"Fisher","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_9","unstructured":"WHO (2023, August 17). WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240060241."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1567-1364.2006.00117.x","article-title":"Candida biofilms on implanted biomaterials: A clinically significant problem","volume":"6","author":"Ramage","year":"2006","journal-title":"FEMS Yeast Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3201\/eid2302.161320","article-title":"Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris","volume":"23","author":"Sherry","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ramage, G., Borghi, E., Rodrigues, C.F., Kean, R., Williams, C., and Lopez-Ribot, J. (2023). Our current clinical understanding of Candida biofilms: Where are we two decades on?. APMIS, in print.","DOI":"10.1111\/apm.13310"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100126","DOI":"10.1016\/j.bioflm.2023.100126","article-title":"Antifungal therapy of Candida biofilms: Past, present and future","volume":"5","author":"Ajetunmobi","year":"2023","journal-title":"Biofilm"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41564-019-0357-1","article-title":"Drug repurposing for antimicrobial discovery","volume":"4","author":"Farha","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00924-20","DOI":"10.1128\/AAC.00924-20","article-title":"Screening repurposing libraries for identification of drugs with novel antifungal activity","volume":"64","author":"Wall","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The drug repurposing hub: A next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/nprot.2008.141","article-title":"A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing","volume":"3","author":"Pierce","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1128\/AAC.45.9.2475-2479.2001","article-title":"Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms","volume":"45","author":"Ramage","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-0716-3155-3_5","article-title":"A 384-well microtiter plate model for Candida biofilm formation and its application to high-throughput screening","volume":"2658","author":"Ajetunmobi","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"ref_20","unstructured":"Clinical and Laboratory Standards Institute (2008). Approved Standard, Clinical and Laboratory Standards Institute. [2nd ed.]. Clsi Document M27-A3."},{"key":"ref_21","unstructured":"Clinical and Laboratory Standards Institute (2008). Approved Standard, Clinical and Laboratory Standards Institute. [2nd ed.]. Clsi Document M38-A2."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e02233-18","DOI":"10.1128\/AAC.02233-18","article-title":"The fungal cyp51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e02198-19","DOI":"10.1128\/AAC.02198-19","article-title":"The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against Candida auris","volume":"64","author":"Wiederhold","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/QCO.0000000000000203","article-title":"What\u2019s new in antifungals: An update on the in-vitro activity and in-vivo efficacy of new and investigational antifungal agents","volume":"28","author":"Wiederhold","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e01084-18","DOI":"10.1128\/AAC.01084-18","article-title":"Screening a repurposing library for inhibitors of multidrug-resistant Candida auris identifies ebselen as a repositionable candidate for antifungal drug development","volume":"62","author":"Wall","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00539-18","DOI":"10.1128\/mSphere.00539-18","article-title":"Alexidine dihydrochloride has broad-spectrum activities against diverse fungal pathogens","volume":"3","author":"Mamouei","year":"2018","journal-title":"mSphere"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1128\/AAC.00680-13","article-title":"High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors","volume":"57","author":"Siles","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"597931","DOI":"10.3389\/fcimb.2020.597931","article-title":"Screening the CALIBR ReFRAME library in search for inhibitors of Candida auris biofilm formation","volume":"10","author":"Wall","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jgar.2020.01.002","article-title":"Identification of repositionable drugs with novel antimycotic activity by screening the Prestwick Chemical Library against emerging invasive moulds","volume":"21","author":"Yousfi","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hong, J., Huang, J., Shen, L., Zhu, S., Gao, W., Wu, J., Huang, O., He, J., Zhu, L., and Chen, W. (2020). A prospective, randomized study of toremifene vs. Tamoxifen for the treatment of premenopausal breast cancer: Safety and genital symptom analysis. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07156-x"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5306\/wjco.v5.i3.393","article-title":"Toremifene in the treatment of breast cancer","volume":"5","author":"Mustonen","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.4049\/jimmunol.1502135","article-title":"Experimental anti-inflammatory drug semapimod inhibits TLR signaling by targeting the TLR chaperone gp96","volume":"196","author":"Wang","year":"2016","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gut.2009.179994","article-title":"A randomised placebo-controlled multicentre trial of intravenous semapimod HCL for moderate to severe crohn\u2019s disease","volume":"59","author":"Dotan","year":"2010","journal-title":"Gut"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.stem.2012.11.015","article-title":"Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen","volume":"12","author":"Gan","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_35","first-page":"648","article-title":"Darapladib, a reversible lipoprotein-associated phospholipase a2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease","volume":"12","author":"Riley","year":"2009","journal-title":"IDrugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrd4381","article-title":"Gsk\u2019s darapladib failures dim hopes for anti-inflammatory heart drugs","volume":"13","author":"Mullard","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/jid.2013.33","article-title":"Photosensitizing agents and the risk of non-melanoma skin cancer: A population-based case-control study","volume":"133","author":"Robinson","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1021\/ml200070g","article-title":"Inhibitors of ketohexokinase: Discovery of pyrimidinopyrimidines with specific substitution that complements the atp-binding site","volume":"2","author":"Maryanoff","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_39","first-page":"1982","article-title":"Bithionol as an antibacterial, antifungal and antihelminthic agent","volume":"23","author":"Kaliszewicz","year":"1968","journal-title":"Pol. Tyg. Lek."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/0006-2952(89)90599-6","article-title":"The photochemical binding of bithionol to soluble proteins and peptides","volume":"38","author":"Delahanty","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","article-title":"Rapamycin: One drug, many effects","volume":"19","author":"Li","year":"2014","journal-title":"Cell Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7164\/antibiotics.28.727","article-title":"Rapamycin (ay-22,989), a new antifungal antibiotiC. II. Fermentation, isolation and characterization","volume":"28","author":"Sehgal","year":"1975","journal-title":"J. Antibiot."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (ay-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J. Antibiot."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"ix87","DOI":"10.1093\/annonc\/mdm299","article-title":"Temsirolimus in the treatment of advanced renal cell carcinoma","volume":"18","author":"Gore","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1756287215574457","article-title":"Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma","volume":"7","author":"Zanardi","year":"2015","journal-title":"Ther. Adv. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/fca-2017-0091","article-title":"Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: A systematic review","volume":"14","author":"Yang","year":"2018","journal-title":"Future Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ajetunmobi, O.H., Chaturvedi, A.K., Badali, H., Vaccaro, A., Najvar, L., Wormley, F.L., Wiederhold, N.P., Patterson, T.F., and Lopez-Ribot, J.L. (2023). Screening the medicine for malaria venture\u2019s pandemic response box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation. APMIS.","DOI":"10.1111\/apm.13342"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1358\/dot.2007.43.10.1148059","article-title":"Temsirolimus","volume":"43","author":"Ma","year":"2007","journal-title":"Drugs Today"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/bcp.13181","article-title":"Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: A report from the children\u2019s oncology group","volume":"83","author":"Mizuno","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1188\/08.CJON.639-646","article-title":"Temsirolimus, an mtor inhibitor for treatment of patients with advanced renal cell carcinoma","volume":"12","author":"Malizzia","year":"2008","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-07-4719","article-title":"Temsirolimus, an inhibitor of mammalian target of rapamycin","volume":"14","author":"Rini","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma","volume":"15","author":"Kwitkowski","year":"2010","journal-title":"Oncologist"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/cam4.3672","article-title":"A phase I trial of the mtor inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies","volume":"10","author":"Trivedi","year":"2021","journal-title":"Cancer Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"21096","DOI":"10.1074\/jbc.272.34.21096","article-title":"Novel inhibitors of cytokine-induced ikappabalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo","volume":"272","author":"Pierce","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"416036","DOI":"10.1155\/2012\/416036","article-title":"Bay 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets","volume":"2012","author":"Lee","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1042\/CS20160645","article-title":"BAY 11-7082 inhibits the NF-kappab and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis","volume":"131","author":"Irrera","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1536\/ihj.51.348","article-title":"Bay 11-7082, a nuclear factor-kappab inhibitor, reduces inflammation and apoptosis in a rat cardiac ischemia-reperfusion injury model","volume":"51","author":"Kim","year":"2010","journal-title":"Int. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.canlet.2008.03.045","article-title":"Bay 11-7082 induces cell death through nf-kappab-independent mechanisms in the ewing\u2019s sarcoma family of tumours","volume":"268","author":"White","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_59","unstructured":"Martinez-Delgado, L. (2018). Repurposing for Antifungal Drug Development: Large-Scale Screening of the Library of Pharmacologically Active Compounds (LOPAC\u00ae1280) for Identification of Candida albicans Biofilm Inhibitors. [Master\u2019s Thesis, The University of Texas at San Antonio]."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3389\/fmicb.2015.01453","article-title":"Screening of pharmacologically active small molecule compounds identifies antifungal agents against Candida biofilms","volume":"6","author":"Watamoto","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"675300","DOI":"10.3389\/fphar.2021.675300","article-title":"Repurposing kinase inhibitor BAY 11-7085 to combat Staphylococcus aureus and Candida albicans biofilms","volume":"12","author":"Escobar","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e0050323","DOI":"10.1128\/aac.00503-23","article-title":"Imaging-based screening identifies modulators of the eif3 translation initiation factor complex in Candida albicans","volume":"67","author":"Metzner","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fcimb.2019.00083","article-title":"Identification of off-patent compounds that present antifungal activity against the emerging fungal pathogen Candida auris","volume":"9","author":"Monteiro","year":"2019","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1007\/s11033-014-3417-x","article-title":"Ebselen, a promising antioxidant drug: Mechanisms of action and targets of biological pathways","volume":"41","author":"Azad","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0140-6736(17)31791-9","article-title":"Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"390","author":"Kil","year":"2017","journal-title":"Lancet"}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/9\/879\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:39:54Z","timestamp":1760128794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/9\/879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jof9090879"],"URL":"https:\/\/doi.org\/10.3390\/jof9090879","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,27]]}}}